Jazz Pharmaceuticals PLC Q2 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : I have one short one, so I'm going to try and sneak in a second one as well. The first one is, what was the year-over-year change in oxybate revenue bottle volume this quarter? And the second one is, can you frame for investors the reason for either confidence or caution heading into the nabiximols Phase III data in MS spasticity? And can you provide the timing for the readout of each of those trials? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 03, 2021 / 8:30PM, JAZZ.OQ - Q2 2021 Jazz Pharmaceuticals PLC Earnings Call

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Just for this quarter or going forward?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : Given that Xywav's share of total oxybate patients has accelerated nicely since launch now you're at about 1/3 of total, it sounds like we're reaching a point where that will level out more. Perhaps there was some lower hanging fruit with the early adopters, like Dan said earlier. So just walk through the next steps of the ramp in more detail, how you plan to broaden the prescriber base and patients that are Xyrem-naive versus switches from Xyrem. And then with IH, if you get that approval, do you think that's going to further provide a tailwind for the narcolepsy indication as well?